ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

NCT04904185 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Evaluation of step A did not support addition of pembrolizumab in step B

Conditions

Malignant Melanoma

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine Phosphate
BIOLOGICAL: Multiple Antigen Specific Endogenously derived T cells
DRUG: Pembrolizumab

Sponsor

Inge Marie Svane

Collaborators

[object Object]